HK1210724A1 - Interleukin-13 antibody composition 13 - Google Patents

Interleukin-13 antibody composition 13

Info

Publication number
HK1210724A1
HK1210724A1 HK15111703.8A HK15111703A HK1210724A1 HK 1210724 A1 HK1210724 A1 HK 1210724A1 HK 15111703 A HK15111703 A HK 15111703A HK 1210724 A1 HK1210724 A1 HK 1210724A1
Authority
HK
Hong Kong
Prior art keywords
interleukin
antibody composition
antibody
composition
Prior art date
Application number
HK15111703.8A
Other languages
English (en)
Chinese (zh)
Inventor
布倫丹‧
‧菲什
珍妮特‧
‧蘭斯通
卡倫‧班尼斯特
克萊爾‧
‧霍普
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37434894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1210724(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0519923.7A external-priority patent/GB0519923D0/en
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of HK1210724A1 publication Critical patent/HK1210724A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HK15111703.8A 2005-09-30 2015-11-27 Interleukin-13 antibody composition 13 HK1210724A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72197405P 2005-09-30 2005-09-30
GBGB0519923.7A GB0519923D0 (en) 2005-09-30 2005-09-30 Interleukin-13 antibody composition

Publications (1)

Publication Number Publication Date
HK1210724A1 true HK1210724A1 (en) 2016-05-06

Family

ID=37434894

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111703.8A HK1210724A1 (en) 2005-09-30 2015-11-27 Interleukin-13 antibody composition 13

Country Status (20)

Country Link
US (3) US20080248048A1 (fr)
EP (1) EP1942939B2 (fr)
JP (2) JP2009510046A (fr)
KR (1) KR101363777B1 (fr)
AU (1) AU2006296399B2 (fr)
BR (1) BRPI0616359B8 (fr)
CA (1) CA2623429C (fr)
CY (2) CY1120874T1 (fr)
FI (1) FIC20210042I1 (fr)
FR (1) FR21C1055I2 (fr)
GB (1) GB2430883B (fr)
HK (1) HK1210724A1 (fr)
HU (1) HUS2100053I1 (fr)
IL (3) IL189983A (fr)
LT (1) LTPA2021528I1 (fr)
NL (1) NL301143I2 (fr)
NO (2) NO344859B1 (fr)
PL (1) PL1942939T5 (fr)
SI (1) SI1942939T2 (fr)
WO (1) WO2007036745A2 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420086B2 (en) * 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
CN104013957B (zh) 2003-12-23 2016-06-29 泰勒公司 用新的抗il13单克隆抗体治疗癌症
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
RU2466740C2 (ru) 2006-04-05 2012-11-20 Эбботт Байотекнолоджи Лтд. Очистка антитела
JP5419709B2 (ja) * 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
US7951368B2 (en) 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
WO2009009406A1 (fr) * 2007-07-06 2009-01-15 Smithkline Beecham Corporation Formulations d'anticorps
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
EP2631302A3 (fr) 2008-03-31 2014-01-08 Genentech, Inc. Compositions et procédés pour traiter et diagnostiquer l'asthme
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
LT3037104T (lt) 2009-10-20 2020-09-10 Abbvie Inc. Anti-il-13 antikūnų izoliavimas ir gryninimas, naudojant afininę baltymo a chromatografiją
CA2817380C (fr) 2010-12-16 2019-06-04 Genentech, Inc. Diagnostic et traitements associes a l'inhibition de th2
JP2014510730A (ja) 2011-03-16 2014-05-01 サノフイ デュアルｖ領域抗体様タンパク質の使用
CA2832560A1 (fr) * 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations a viscosite reduite
SG10201505454SA (en) 2011-07-13 2015-09-29 Abbvie Inc Methods and compositions for treating asthma using anti-il-13 antibodies
FI3091029T3 (fi) 2011-10-31 2023-03-20 Hoffmann La Roche Anti-il13-vasta-aineformulaatioita
RU2014139546A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Методы прогнозирования, диагностики и лечения идиопатического легочного фиброза
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
NZ756750A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
KR20160068802A (ko) 2013-10-23 2016-06-15 제넨테크, 인크. 호산구성 장애를 진단 및 치료하는 방법
JP2014062100A (ja) * 2013-11-05 2014-04-10 Glaxosmithkline Llc 抗体処方
KR20160124165A (ko) 2014-02-21 2016-10-26 제넨테크, 인크. 항-il-13/il-17 이중특이적 항체 및 그의 용도
NZ723336A (en) * 2014-02-27 2017-04-28 Univ Texas Methods and compositions for isolating exosomes
WO2015155710A1 (fr) 2014-04-11 2015-10-15 Novartis Ag Méthodes de traitement sélectif de l'asthme au moyen d'antagonistes de l'il-13
JP6247241B2 (ja) * 2015-02-27 2017-12-13 ノバルティス アーゲー 抗体処方
MX2017011486A (es) 2015-03-16 2018-06-15 Genentech Inc Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
WO2017139290A1 (fr) * 2016-02-10 2017-08-17 Medimmune, Llc Dispositif d'administration de tralokinumab
RS64550B1 (sr) 2016-09-23 2023-09-29 Hoffmann La Roche Upotreba il-13 antagonista za lečenje atopičnog dermatitisa
BR112019022873A8 (pt) 2017-05-02 2023-04-11 Merck Sharp & Dohme Formulação, e, vaso ou dispositivo de injeção.
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7418337B2 (ja) 2018-02-09 2024-01-19 ジェネンテック， インコーポレイテッド マスト細胞媒介性炎症性疾患の治療法及び診断法
WO2020092015A1 (fr) 2018-11-02 2020-05-07 University Of Rochester Atténuation thérapeutique d'une infection épithéliale
WO2021191220A1 (fr) 2020-03-23 2021-09-30 Medimmune Limited Méthodes de traitement de la dermatite atopique et des troubles associés
GB202108379D0 (en) 2021-06-11 2021-07-28 Medlmmune Ltd Methods for treating a topic dermatitis and related disorders
JP2024531300A (ja) 2021-08-16 2024-08-29 メディミューン，エルエルシー 抗ｉｌ－１３抗体製剤
CA3230946A1 (fr) 2021-09-15 2023-03-23 Renata Gontijo LIMA Inhibiteurs de l'il-13 pour le traitement du prurigo nodulaire
WO2023052408A1 (fr) 2021-09-28 2023-04-06 Medimmune Limited Méthodes de traitement de la dermatite atopique et de troubles apparentés

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2685919B1 (fr) 1992-01-08 1994-04-08 Elf Sanofi Proteine a activite de type cytokine, adn recombinant codant pour cette proteine, cellules animales transformees.
HU217099B (hu) 1991-03-29 1999-11-29 Elf Sanofi Sa. Eljárás citokin típusú aktivitással rendelkező fehérje, azt kódoló rekombináns DNS-szekvencia és a megfelelő transzformált sejtek és mikroorganizmusok előállítására
US5596072A (en) * 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
JPH07267994A (ja) * 1994-03-31 1995-10-17 Snow Brand Milk Prod Co Ltd 新規蛋白質及びその製造法
JP3414856B2 (ja) * 1994-08-09 2003-06-09 株式会社ヤトロン ジフェニルエーテル化合物の免疫学的測定方法
US5866154A (en) 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
JP2000510692A (ja) 1996-05-04 2000-08-22 ゼネカ リミテッド Ｃｅａに対するモノクローナル抗体、その抗体を含む結合体、およびａｄｅｐｔシステムにおけるそれらの治療的使用
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
DK0999853T3 (da) 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
AU753468B2 (en) 1998-06-09 2002-10-17 Csl Behring Ag Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
JP3537331B2 (ja) * 1998-11-17 2004-06-14 積水化学工業株式会社 Ｉｖ型コラーゲンの免疫測定法及び試薬
JP5198704B2 (ja) 2000-03-03 2013-05-15 メディミューン リミティド エオタキシンに対するヒト抗体及びそれらの使用
EP1175931A1 (fr) 2000-07-25 2002-01-30 Computer Cell Culture Center S.A. Intégration de la mise en oeuvre d'un bioréacteur à haute densité cellulaire avec traitement ultérieur en ligne ultrarapide
WO2003010512A2 (fr) 2001-07-23 2003-02-06 Accurate Polymers, Inc. Separation solide-liquide a grande vitesse
US20040248260A1 (en) * 2001-10-26 2004-12-09 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
US20040234499A1 (en) 2001-10-26 2004-11-25 David Shealy Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
US20040023337A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
WO2003086451A1 (fr) 2002-04-05 2003-10-23 Centocor, Inc. Proteines derivees de l'immunoglobuline anti il-13 associees a l'asthme, compositions, procedes et utilisations associes
WO2004001007A2 (fr) * 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Preparations tamponnees permettant de concentrer des anticorps et procedes pour les utiliser
PT1601697E (pt) 2003-02-28 2007-09-04 Lonza Biologics Plc Purificação de anticorpos através de proteína a e cromatografia de troca iónica.
EP1614693A4 (fr) 2003-03-31 2006-07-19 Kirin Brewery Purification d'un anticorps monoclonal humain et d'un anticorps polyclonal humain
PL1610820T5 (pl) * 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
CN104013957B (zh) 2003-12-23 2016-06-29 泰勒公司 用新的抗il13单克隆抗体治疗癌症
CN1234725C (zh) 2004-04-07 2006-01-04 陈志南 一种高效快速纯化制备片段抗体的方法
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
CA2577631A1 (fr) * 2004-08-20 2006-03-02 Amgen Inc. Procedes et compositions pour le traitement d'inflammation allergique
CA2587903A1 (fr) * 2004-11-17 2006-05-26 Amgen Fremont Inc. Anticorps monoclonaux entierement humains diriges contre l'il-13
US20060171943A1 (en) * 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
WO2012049287A1 (fr) † 2010-10-14 2012-04-19 Ticona Gmbh Polyoxyméthylène plastifié

Also Published As

Publication number Publication date
EP1942939A2 (fr) 2008-07-16
FR21C1055I1 (fr) 2021-12-24
NO344859B1 (no) 2020-06-02
US20160002327A1 (en) 2016-01-07
CA2623429C (fr) 2015-01-13
US20110086038A1 (en) 2011-04-14
IL230005A (en) 2016-05-31
IL230005A0 (en) 2014-01-30
US9107945B2 (en) 2015-08-18
HUS2100053I1 (hu) 2021-12-28
NL301143I1 (fr) 2021-11-10
IL246674B (en) 2019-09-26
WO2007036745A2 (fr) 2007-04-05
NO20081946L (no) 2008-06-27
BRPI0616359A2 (pt) 2011-06-14
PL1942939T5 (pl) 2021-10-11
CY1120874T1 (el) 2019-12-11
GB0619204D0 (en) 2006-11-08
BRPI0616359B8 (pt) 2022-08-30
JP2014040461A (ja) 2014-03-06
CY2021033I1 (el) 2022-03-24
LTPA2021528I1 (fr) 2021-12-27
AU2006296399A1 (en) 2007-04-05
GB2430883B (en) 2008-03-19
KR20080054429A (ko) 2008-06-17
EP1942939B2 (fr) 2021-07-07
FIC20210042I1 (fi) 2021-11-23
JP2009510046A (ja) 2009-03-12
CA2623429A1 (fr) 2007-04-05
EP1942939B1 (fr) 2018-05-30
SI1942939T2 (sl) 2021-11-30
FR21C1055I2 (fr) 2022-11-18
AU2006296399A8 (en) 2008-07-17
IL246674A0 (en) 2016-08-31
IL189983A0 (en) 2008-08-07
PL1942939T3 (pl) 2018-10-31
US20080248048A1 (en) 2008-10-09
WO2007036745A3 (fr) 2007-08-02
AU2006296399B2 (en) 2011-01-20
GB2430883A (en) 2007-04-11
IL189983A (en) 2016-11-30
KR101363777B1 (ko) 2014-02-14
JP5820450B2 (ja) 2015-11-24
BRPI0616359B1 (pt) 2021-09-08
US10358488B2 (en) 2019-07-23
NO2021050I1 (no) 2021-11-12
SI1942939T1 (sl) 2018-10-30
NL301143I2 (nl) 2022-02-10

Similar Documents

Publication Publication Date Title
HUS2100053I1 (hu) Interleukin-13-antitest-készítmény
IL185380A0 (en) ANTI-MAdCAM ANTIBODY COMPOSITIONS
IL229521A0 (en) A new preparation
IL185901A0 (en) Novel composition
GB0409375D0 (en) Phytoactive composition
IL187316A0 (en) Anti-interleukin 2 antibodies
EP1726304A4 (fr) Composition contenant de la solifenacine
GB0416861D0 (en) Composition
GB0410038D0 (en) Composition
GB0414803D0 (en) Composition
GB0415981D0 (en) Composition
GB0505760D0 (en) Novel composition
GB0417357D0 (en) Composition
GB0513367D0 (en) Novel composition
ZA200802413B (en) Interleukin-13 antibody composition
HK1101657A2 (en) Novel composition
GB0417388D0 (en) Composition
GB0409598D0 (en) Composition
GB0516614D0 (en) Novel composition
ZA200707916B (en) Novel composition
GB0525458D0 (en) Novel composition
GB0502077D0 (en) Novel composition
GB0416436D0 (en) Composition
GB0415329D0 (en) Composition
GB0415334D0 (en) Composition